on BIOMERIEUX (EPA:BIM)
BioMérieux Receives CE-Marking for VIDAS® Vitamin B12 Test
bioMérieux, a global leader in in vitro diagnostics, has announced the CE-marking for its VIDAS® VITAMIN B12 TOTAL test. This automated quantitative test measures total Vitamin B12 concentration in human serum or plasma, utilizing VIDAS® immunoassay instruments. Vitamin B12 is crucial for DNA synthesis, nervous system health, and red blood cell formation. Deficiencies can lead to anemia or neurological symptoms.
The new test aids in assessing vitamin B12 status in adults with suspected deficiencies or risk factors. It is compatible with all VIDAS® immunoanalysers, enhancing throughput and traceability in labs. The test strengthens the VIDAS® anemia-targeting assay lineup, aligning with bioMérieux's strategic focus on immunoassays and patient care optimization.
VIDAS® VITAMIN B12 TOTAL is set for commercial launch in select countries by the end of 2024, with an expanded rollout in early 2025.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BIOMERIEUX news